In an open-label, single-arm, phase II study presented at the 2019 Gastrointestinal Cancers Symposium, 28 evaluable patients with initial stage II, III, or IV disease, were treated with the regimen, which is comprised of a tyrosine derivative (D,L-alpha-metyrosine), an mTOR inhibitor (sirolimus), a CYP3a4 inducer (phenytoin), and an oxidative stress catalyst (methoxsalen). After a median follow-up of 4.3 months after treatment initiation, 67.8% of patients were alive and still on treatment, said Ocean, who is an associate professor of clinical medicine at Weill Cornell Medicine and NewYork-Presbyterian. Read more . . .